Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials.

Ciudin A, Sapin H, Fan L, Dimitriadis GK, Zimner-Rapuch S, Curteis T, Clark LJ, Rubinstein M, Johansson E

Advances in therapy12 Mar 2026Cited by 3 (Europe PMC)

PMID41820778PMCIDPMC13156185DOI10.1007/s12325-026-03523-5PepBankPUB-41820778

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study24

21 results from studies that gave the peptide. 21 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with obesity or overweight without type 2 diabetes, tirzepatide 5 mg had statistically greater improvement in weight reduction outcomes than liraglutide.
In plain wordsIn adults with obesity or overweight without type 2 diabetes, tirzepatide 5 mg improved weight reduction more than liraglutide.
Peptide
Tirzepatide
Outcome
DecreaseWeight reduction outcomes
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
5 mgAs given in this study (human).
Source sentences
Summary
all tirzepatide doses were associated with statistically greater improvements in weight reduction outcomes versus liraglutide
2 context sentences(design, population, supporting numbers)
Summary · context
Based on a systematic literature review (SLR) and Bayesian network meta-analysis (NMA), the efficacy and safety of semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide 5, 10 and 15 mg were compared in adults without type 2 diabetes, and with either obesity (body mass index [BMI] ≥ 30 kg/m2</sup…
Summary · context
Following a stringent heterogeneity assessment, six of 42 randomised controlled trials identified in the SLR were included in the NMA.
Report a problemFND-4182077801
02HumanSystematic reviewEfficacy outcome
In adults with obesity or overweight without type 2 diabetes, tirzepatide 10 mg had a reported percentage weight reduction difference of -12.86% versus liraglutide.
In plain wordsIn adults with obesity or overweight without type 2 diabetes, tirzepatide 10 mg reduced weight more than liraglutide.
Peptide
Tirzepatide
Outcome
DecreasePercentage weight reduction
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
10 mgAs given in this study (human).
Measurements
Percentage weight reduction
−12.86%
tirzepatide 10 mg versus liraglutide
Source sentences
Summary
including percentage weight reduction (- 12.86% for tirzepatide 10 mg and - 13.95% for tirzepatide 15 mg versus liraglutide
2 context sentences(design, population, supporting numbers)
Summary · context
Based on a systematic literature review (SLR) and Bayesian network meta-analysis (NMA), the efficacy and safety of semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide 5, 10 and 15 mg were compared in adults without type 2 diabetes, and with either obesity (body mass index [BMI] ≥ 30 kg/m2</sup…
Summary · context
Following a stringent heterogeneity assessment, six of 42 randomised controlled trials identified in the SLR were included in the NMA.
Report a problemFND-4182077802
03HumanSystematic reviewEfficacy outcome
In adults with obesity or overweight without type 2 diabetes, tirzepatide 10 mg had a reported waist circumference difference of -11.79cm versus liraglutide.
In plain wordsIn adults with obesity or overweight without type 2 diabetes, tirzepatide 10 mg reduced waist size more than liraglutide.
Peptide
Tirzepatide
Outcome
DecreaseWaist circumference
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Body composition · Metabolic and weight
Studied dose
10 mgAs given in this study (human).
Measurements
Waist circumference difference
−11.79 cm
tirzepatide 10 mg versus liraglutide
Source sentences
Summary
and waist circumference (- 11.79 cm and - 12.30 cm versus liraglutide
2 context sentences(design, population, supporting numbers)
Summary · context
Based on a systematic literature review (SLR) and Bayesian network meta-analysis (NMA), the efficacy and safety of semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide 5, 10 and 15 mg were compared in adults without type 2 diabetes, and with either obesity (body mass index [BMI] ≥ 30 kg/m2</sup…
Summary · context
Following a stringent heterogeneity assessment, six of 42 randomised controlled trials identified in the SLR were included in the NMA.
Report a problemFND-4182077803
04HumanSystematic reviewEfficacy outcome
In adults with obesity or overweight without type 2 diabetes, tirzepatide 15 mg had a reported percentage weight reduction difference of -13.95% versus liraglutide.
In plain wordsIn adults with obesity or overweight without type 2 diabetes, tirzepatide 15 mg reduced weight more than liraglutide.
Peptide
Tirzepatide
Outcome
DecreasePercentage weight reduction
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Measurements
Percentage weight reduction
−13.95%
tirzepatide 15 mg versus liraglutide
Source sentences
Summary
including percentage weight reduction (- 12.86% for tirzepatide 10 mg and - 13.95% for tirzepatide 15 mg versus liraglutide
2 context sentences(design, population, supporting numbers)
Summary · context
Based on a systematic literature review (SLR) and Bayesian network meta-analysis (NMA), the efficacy and safety of semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide 5, 10 and 15 mg were compared in adults without type 2 diabetes, and with either obesity (body mass index [BMI] ≥ 30 kg/m2</sup…
Summary · context
Following a stringent heterogeneity assessment, six of 42 randomised controlled trials identified in the SLR were included in the NMA.
Report a problemFND-4182077804
05HumanSystematic reviewEfficacy outcome
In adults with obesity or overweight without type 2 diabetes, tirzepatide 15 mg had a reported waist circumference difference of -12.3cm versus liraglutide.
In plain wordsIn adults with obesity or overweight without type 2 diabetes, tirzepatide 15 mg reduced waist size more than liraglutide.
Peptide
Tirzepatide
Outcome
DecreaseWaist circumference
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Body composition · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Measurements
Waist circumference difference
−12.3 cm
tirzepatide 15 mg versus liraglutide
Source sentences
Summary
and waist circumference (- 11.79 cm and - 12.30 cm versus liraglutide
2 context sentences(design, population, supporting numbers)
Summary · context
Based on a systematic literature review (SLR) and Bayesian network meta-analysis (NMA), the efficacy and safety of semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide 5, 10 and 15 mg were compared in adults without type 2 diabetes, and with either obesity (body mass index [BMI] ≥ 30 kg/m2</sup…
Summary · context
Following a stringent heterogeneity assessment, six of 42 randomised controlled trials identified in the SLR were included in the NMA.
Report a problemFND-4182077805
06HumanSystematic reviewEfficacy outcome
In adults with obesity or overweight without type 2 diabetes, tirzepatide 10 mg had a reported percentage weight reduction difference of -4.85% versus semaglutide.
In plain wordsIn adults with obesity or overweight without type 2 diabetes, tirzepatide 10 mg reduced weight more than semaglutide.
Peptide
Tirzepatide
Outcome
DecreasePercentage weight reduction
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
10 mgAs given in this study (human).
Measurements
Percentage weight reduction
−4.85%
tirzepatide 10 mg versus semaglutide
Source sentences
Summary
and for tirzepatide 10 and 15 mg versus semaglutide: including percentage weight reduction (- 12.86% for tirzepatide 10 mg and - 13.95% for tirzepatide 15 mg versus liraglutide; - 4.85% and - 6.26% versus semaglutide)
2 context sentences(design, population, supporting numbers)
Summary · context
Based on a systematic literature review (SLR) and Bayesian network meta-analysis (NMA), the efficacy and safety of semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide 5, 10 and 15 mg were compared in adults without type 2 diabetes, and with either obesity (body mass index [BMI] ≥ 30 kg/m2</sup…
Summary · context
Following a stringent heterogeneity assessment, six of 42 randomised controlled trials identified in the SLR were included in the NMA.
Report a problemFND-4182077806
07HumanSystematic reviewEfficacy outcome
In adults with obesity or overweight without type 2 diabetes, tirzepatide 10 mg had a reported waist circumference difference of -4.81cm versus semaglutide.
In plain wordsIn adults with obesity or overweight without type 2 diabetes, tirzepatide 10 mg reduced waist size more than semaglutide.
Peptide
Tirzepatide
Outcome
DecreaseWaist circumference
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Body composition · Metabolic and weight
Studied dose
10 mgAs given in this study (human).
Measurements
Waist circumference difference
−4.81 cm
tirzepatide 10 mg versus semaglutide
Source sentences
Summary
for tirzepatide 10 and 15 mg versus semaglutide: including percentage weight reduction (- 12.86% for tirzepatide 10 mg and - 13.95% for tirzepatide 15 mg versus liraglutide; - 4.85% and - 6.26% versus semaglutide) and waist circumference (- 11.79 cm and - 12.30 cm versus liraglutide; - 4.81 cm and -…
2 context sentences(design, population, supporting numbers)
Summary · context
Based on a systematic literature review (SLR) and Bayesian network meta-analysis (NMA), the efficacy and safety of semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide 5, 10 and 15 mg were compared in adults without type 2 diabetes, and with either obesity (body mass index [BMI] ≥ 30 kg/m2</sup…
Summary · context
Following a stringent heterogeneity assessment, six of 42 randomised controlled trials identified in the SLR were included in the NMA.
Report a problemFND-4182077807
08HumanSystematic reviewEfficacy outcome
In adults with obesity or overweight without type 2 diabetes, tirzepatide 15 mg had a reported percentage weight reduction difference of -6.26% versus semaglutide.
In plain wordsIn adults with obesity or overweight without type 2 diabetes, tirzepatide 15 mg reduced weight more than semaglutide.
Peptide
Tirzepatide
Outcome
DecreasePercentage weight reduction
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Measurements
Percentage weight reduction
−6.26%
tirzepatide 15 mg versus semaglutide
Source sentences
Summary
and for tirzepatide 10 and 15 mg versus semaglutide: including percentage weight reduction (- 12.86% for tirzepatide 10 mg and - 13.95% for tirzepatide 15 mg versus liraglutide; - 4.85% and - 6.26% versus semaglutide)
2 context sentences(design, population, supporting numbers)
Summary · context
Based on a systematic literature review (SLR) and Bayesian network meta-analysis (NMA), the efficacy and safety of semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide 5, 10 and 15 mg were compared in adults without type 2 diabetes, and with either obesity (body mass index [BMI] ≥ 30 kg/m2</sup…
Summary · context
Following a stringent heterogeneity assessment, six of 42 randomised controlled trials identified in the SLR were included in the NMA.
Report a problemFND-4182077808
09HumanSystematic reviewEfficacy outcome
In adults with obesity or overweight without type 2 diabetes, tirzepatide 15 mg had a reported waist circumference difference of -5.32cm versus semaglutide.
In plain wordsIn adults with obesity or overweight without type 2 diabetes, tirzepatide 15 mg reduced waist size more than semaglutide.
Peptide
Tirzepatide
Outcome
DecreaseWaist circumference
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Body composition · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Measurements
Waist circumference difference
−5.32 cm
tirzepatide 15 mg versus semaglutide
Source sentences
Summary
for tirzepatide 10 and 15 mg versus semaglutide: including percentage weight reduction (- 12.86% for tirzepatide 10 mg and - 13.95% for tirzepatide 15 mg versus liraglutide; - 4.85% and - 6.26% versus semaglutide) and waist circumference (- 11.79 cm and - 12.30 cm versus liraglutide; - 4.81 cm and -…
2 context sentences(design, population, supporting numbers)
Summary · context
Based on a systematic literature review (SLR) and Bayesian network meta-analysis (NMA), the efficacy and safety of semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide 5, 10 and 15 mg were compared in adults without type 2 diabetes, and with either obesity (body mass index [BMI] ≥ 30 kg/m2</sup…
Summary · context
Following a stringent heterogeneity assessment, six of 42 randomised controlled trials identified in the SLR were included in the NMA.
Report a problemFND-4182077809
10HumanSystematic reviewEfficacy outcome
In adults with obesity or overweight without type 2 diabetes, tirzepatide 5 mg had statistically greater triglyceride improvement than liraglutide.
In plain wordsIn adults with obesity or overweight without type 2 diabetes, tirzepatide 5 mg had greater triglyceride improvement than liraglutide.
Peptide
Tirzepatide
Outcome
Direction not reportedTriglycerides
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Lipids · Metabolic and weight
Studied dose
5 mgAs given in this study (human).
Source sentences
Summary
All tirzepatide doses were associated with statistically greater improvements in triglycerides and diastolic blood pressure versus liraglutide, and generally comparable improvements in other glycaemic, lipid and blood pressure parameters versus liraglutide and semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Based on a systematic literature review (SLR) and Bayesian network meta-analysis (NMA), the efficacy and safety of semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide 5, 10 and 15 mg were compared in adults without type 2 diabetes, and with either obesity (body mass index [BMI] ≥ 30 kg/m2</sup…
Summary · context
Following a stringent heterogeneity assessment, six of 42 randomised controlled trials identified in the SLR were included in the NMA.
Report a problemFND-4182077810
11HumanSystematic reviewEfficacy outcome
In adults with obesity or overweight without type 2 diabetes, tirzepatide 5 mg had statistically greater diastolic-blood-pressure improvement than liraglutide.
In plain wordsIn adults with obesity or overweight without type 2 diabetes, tirzepatide 5 mg had greater diastolic-blood-pressure improvement than liraglutide.
Peptide
Tirzepatide
Outcome
Direction not reportedDiastolic blood pressure
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Blood pressure · Cardiovascular
Studied dose
5 mgAs given in this study (human).
Source sentences
Summary
All tirzepatide doses were associated with statistically greater improvements in triglycerides and diastolic blood pressure versus liraglutide, and generally comparable improvements in other glycaemic, lipid and blood pressure parameters versus liraglutide and semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Based on a systematic literature review (SLR) and Bayesian network meta-analysis (NMA), the efficacy and safety of semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide 5, 10 and 15 mg were compared in adults without type 2 diabetes, and with either obesity (body mass index [BMI] ≥ 30 kg/m2</sup…
Summary · context
Following a stringent heterogeneity assessment, six of 42 randomised controlled trials identified in the SLR were included in the NMA.
Report a problemFND-4182077811
12HumanSystematic reviewEfficacy outcome
In adults with obesity or overweight without type 2 diabetes, tirzepatide 10 mg had statistically greater triglyceride improvement than liraglutide.
In plain wordsIn adults with obesity or overweight without type 2 diabetes, tirzepatide 10 mg had greater triglyceride improvement than liraglutide.
Peptide
Tirzepatide
Outcome
Direction not reportedTriglycerides
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Lipids · Metabolic and weight
Studied dose
10 mgAs given in this study (human).
Source sentences
Summary
All tirzepatide doses were associated with statistically greater improvements in triglycerides and diastolic blood pressure versus liraglutide, and generally comparable improvements in other glycaemic, lipid and blood pressure parameters versus liraglutide and semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Based on a systematic literature review (SLR) and Bayesian network meta-analysis (NMA), the efficacy and safety of semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide 5, 10 and 15 mg were compared in adults without type 2 diabetes, and with either obesity (body mass index [BMI] ≥ 30 kg/m2</sup…
Summary · context
Following a stringent heterogeneity assessment, six of 42 randomised controlled trials identified in the SLR were included in the NMA.
Report a problemFND-4182077812
13HumanSystematic reviewEfficacy outcome
In adults with obesity or overweight without type 2 diabetes, tirzepatide 10 mg had statistically greater diastolic-blood-pressure improvement than liraglutide.
In plain wordsIn adults with obesity or overweight without type 2 diabetes, tirzepatide 10 mg had greater diastolic-blood-pressure improvement than liraglutide.
Peptide
Tirzepatide
Outcome
Direction not reportedDiastolic blood pressure
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Blood pressure · Cardiovascular
Studied dose
10 mgAs given in this study (human).
Source sentences
Summary
All tirzepatide doses were associated with statistically greater improvements in triglycerides and diastolic blood pressure versus liraglutide, and generally comparable improvements in other glycaemic, lipid and blood pressure parameters versus liraglutide and semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Based on a systematic literature review (SLR) and Bayesian network meta-analysis (NMA), the efficacy and safety of semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide 5, 10 and 15 mg were compared in adults without type 2 diabetes, and with either obesity (body mass index [BMI] ≥ 30 kg/m2</sup…
Summary · context
Following a stringent heterogeneity assessment, six of 42 randomised controlled trials identified in the SLR were included in the NMA.
Report a problemFND-4182077813
14HumanSystematic reviewEfficacy outcome
In adults with obesity or overweight without type 2 diabetes, tirzepatide 15 mg had statistically greater triglyceride improvement than liraglutide.
In plain wordsIn adults with obesity or overweight without type 2 diabetes, tirzepatide 15 mg had greater triglyceride improvement than liraglutide.
Peptide
Tirzepatide
Outcome
Direction not reportedTriglycerides
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Lipids · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
All tirzepatide doses were associated with statistically greater improvements in triglycerides and diastolic blood pressure versus liraglutide, and generally comparable improvements in other glycaemic, lipid and blood pressure parameters versus liraglutide and semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Based on a systematic literature review (SLR) and Bayesian network meta-analysis (NMA), the efficacy and safety of semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide 5, 10 and 15 mg were compared in adults without type 2 diabetes, and with either obesity (body mass index [BMI] ≥ 30 kg/m2</sup…
Summary · context
Following a stringent heterogeneity assessment, six of 42 randomised controlled trials identified in the SLR were included in the NMA.
Report a problemFND-4182077814
15HumanSystematic reviewEfficacy outcome
In adults with obesity or overweight without type 2 diabetes, tirzepatide 15 mg had statistically greater diastolic-blood-pressure improvement than liraglutide.
In plain wordsIn adults with obesity or overweight without type 2 diabetes, tirzepatide 15 mg had greater diastolic-blood-pressure improvement than liraglutide.
Peptide
Tirzepatide
Outcome
Direction not reportedDiastolic blood pressure
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Blood pressure · Cardiovascular
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
All tirzepatide doses were associated with statistically greater improvements in triglycerides and diastolic blood pressure versus liraglutide, and generally comparable improvements in other glycaemic, lipid and blood pressure parameters versus liraglutide and semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Based on a systematic literature review (SLR) and Bayesian network meta-analysis (NMA), the efficacy and safety of semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide 5, 10 and 15 mg were compared in adults without type 2 diabetes, and with either obesity (body mass index [BMI] ≥ 30 kg/m2</sup…
Summary · context
Following a stringent heterogeneity assessment, six of 42 randomised controlled trials identified in the SLR were included in the NMA.
Report a problemFND-4182077815
16HumanSystematic reviewEfficacy outcome
In adults with obesity or overweight without type 2 diabetes, tirzepatide 5 mg had generally comparable improvements in other glycaemic, lipid and blood pressure parameters versus liraglutide.
In plain wordsIn adults with obesity or overweight without type 2 diabetes, tirzepatide 5 mg had generally comparable other cardiometabolic improvements to liraglutide.
Peptide
Tirzepatide
Outcome
Not applicableOther glycaemic, lipid and blood pressure parameters
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
5 mgAs given in this study (human).
Source sentences
Summary
All tirzepatide doses were associated with statistically greater improvements in triglycerides and diastolic blood pressure versus liraglutide, and generally comparable improvements in other glycaemic, lipid and blood pressure parameters versus liraglutide and semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Based on a systematic literature review (SLR) and Bayesian network meta-analysis (NMA), the efficacy and safety of semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide 5, 10 and 15 mg were compared in adults without type 2 diabetes, and with either obesity (body mass index [BMI] ≥ 30 kg/m2</sup…
Summary · context
Following a stringent heterogeneity assessment, six of 42 randomised controlled trials identified in the SLR were included in the NMA.
Report a problemFND-4182077819
17HumanSystematic reviewEfficacy outcome
In adults with obesity or overweight without type 2 diabetes, tirzepatide 5 mg had generally comparable improvements in other glycaemic, lipid and blood pressure parameters versus semaglutide.
In plain wordsIn adults with obesity or overweight without type 2 diabetes, tirzepatide 5 mg had generally comparable other cardiometabolic improvements to semaglutide.
Peptide
Tirzepatide
Outcome
Not applicableOther glycaemic, lipid and blood pressure parameters
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
5 mgAs given in this study (human).
Source sentences
Summary
All tirzepatide doses were associated with statistically greater improvements in triglycerides and diastolic blood pressure versus liraglutide, and generally comparable improvements in other glycaemic, lipid and blood pressure parameters versus liraglutide and semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Based on a systematic literature review (SLR) and Bayesian network meta-analysis (NMA), the efficacy and safety of semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide 5, 10 and 15 mg were compared in adults without type 2 diabetes, and with either obesity (body mass index [BMI] ≥ 30 kg/m2</sup…
Summary · context
Following a stringent heterogeneity assessment, six of 42 randomised controlled trials identified in the SLR were included in the NMA.
Report a problemFND-4182077820
18HumanSystematic reviewEfficacy outcome
In adults with obesity or overweight without type 2 diabetes, tirzepatide 10 mg had generally comparable improvements in other glycaemic, lipid and blood pressure parameters versus liraglutide.
In plain wordsIn adults with obesity or overweight without type 2 diabetes, tirzepatide 10 mg had generally comparable other cardiometabolic improvements to liraglutide.
Peptide
Tirzepatide
Outcome
Not applicableOther glycaemic, lipid and blood pressure parameters
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
10 mgAs given in this study (human).
Source sentences
Summary
All tirzepatide doses were associated with statistically greater improvements in triglycerides and diastolic blood pressure versus liraglutide, and generally comparable improvements in other glycaemic, lipid and blood pressure parameters versus liraglutide and semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Based on a systematic literature review (SLR) and Bayesian network meta-analysis (NMA), the efficacy and safety of semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide 5, 10 and 15 mg were compared in adults without type 2 diabetes, and with either obesity (body mass index [BMI] ≥ 30 kg/m2</sup…
Summary · context
Following a stringent heterogeneity assessment, six of 42 randomised controlled trials identified in the SLR were included in the NMA.
Report a problemFND-4182077821
19HumanSystematic reviewEfficacy outcome
In adults with obesity or overweight without type 2 diabetes, tirzepatide 10 mg had generally comparable improvements in other glycaemic, lipid and blood pressure parameters versus semaglutide.
In plain wordsIn adults with obesity or overweight without type 2 diabetes, tirzepatide 10 mg had generally comparable other cardiometabolic improvements to semaglutide.
Peptide
Tirzepatide
Outcome
Not applicableOther glycaemic, lipid and blood pressure parameters
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
10 mgAs given in this study (human).
Source sentences
Summary
All tirzepatide doses were associated with statistically greater improvements in triglycerides and diastolic blood pressure versus liraglutide, and generally comparable improvements in other glycaemic, lipid and blood pressure parameters versus liraglutide and semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Based on a systematic literature review (SLR) and Bayesian network meta-analysis (NMA), the efficacy and safety of semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide 5, 10 and 15 mg were compared in adults without type 2 diabetes, and with either obesity (body mass index [BMI] ≥ 30 kg/m2</sup…
Summary · context
Following a stringent heterogeneity assessment, six of 42 randomised controlled trials identified in the SLR were included in the NMA.
Report a problemFND-4182077822
20HumanSystematic reviewEfficacy outcome
In adults with obesity or overweight without type 2 diabetes, tirzepatide 15 mg had generally comparable improvements in other glycaemic, lipid and blood pressure parameters versus liraglutide.
In plain wordsIn adults with obesity or overweight without type 2 diabetes, tirzepatide 15 mg had generally comparable other cardiometabolic improvements to liraglutide.
Peptide
Tirzepatide
Outcome
Not applicableOther glycaemic, lipid and blood pressure parameters
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
All tirzepatide doses were associated with statistically greater improvements in triglycerides and diastolic blood pressure versus liraglutide, and generally comparable improvements in other glycaemic, lipid and blood pressure parameters versus liraglutide and semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Based on a systematic literature review (SLR) and Bayesian network meta-analysis (NMA), the efficacy and safety of semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide 5, 10 and 15 mg were compared in adults without type 2 diabetes, and with either obesity (body mass index [BMI] ≥ 30 kg/m2</sup…
Summary · context
Following a stringent heterogeneity assessment, six of 42 randomised controlled trials identified in the SLR were included in the NMA.
Report a problemFND-4182077823
21HumanSystematic reviewEfficacy outcome
In adults with obesity or overweight without type 2 diabetes, tirzepatide 15 mg had generally comparable improvements in other glycaemic, lipid and blood pressure parameters versus semaglutide.
In plain wordsIn adults with obesity or overweight without type 2 diabetes, tirzepatide 15 mg had generally comparable other cardiometabolic improvements to semaglutide.
Peptide
Tirzepatide
Outcome
Not applicableOther glycaemic, lipid and blood pressure parameters
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Source sentences
Summary
All tirzepatide doses were associated with statistically greater improvements in triglycerides and diastolic blood pressure versus liraglutide, and generally comparable improvements in other glycaemic, lipid and blood pressure parameters versus liraglutide and semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Based on a systematic literature review (SLR) and Bayesian network meta-analysis (NMA), the efficacy and safety of semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide 5, 10 and 15 mg were compared in adults without type 2 diabetes, and with either obesity (body mass index [BMI] ≥ 30 kg/m2</sup…
Summary · context
Following a stringent heterogeneity assessment, six of 42 randomised controlled trials identified in the SLR were included in the NMA.
Report a problemFND-4182077824

Studies that did not test the peptide alone3

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

22HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In the network meta-analysis, all interventions had a comparable safety profile.
In plain wordsIn adults with obesity or overweight without type 2 diabetes, pooled tirzepatide, liraglutide and semaglutide interventions had a comparable overall safety profile.
Peptide
Liraglutide
Outcome
Not applicableOverall safety profile
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
All interventions had a comparable safety profile.
2 context sentences(design, population, supporting numbers)
Summary · context
Based on a systematic literature review (SLR) and Bayesian network meta-analysis (NMA), the efficacy and safety of semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide 5, 10 and 15 mg were compared in adults without type 2 diabetes, and with either obesity (body mass index [BMI] ≥ 30 kg/m2</sup…
Summary · context
Following a stringent heterogeneity assessment, six of 42 randomised controlled trials identified in the SLR were included in the NMA.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4182077816
23HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In the network meta-analysis, all interventions had a comparable safety profile.
In plain wordsIn adults with obesity or overweight without type 2 diabetes, pooled tirzepatide, liraglutide and semaglutide interventions had a comparable overall safety profile.
Peptide
Semaglutide
Outcome
Not applicableOverall safety profile
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
All interventions had a comparable safety profile.
2 context sentences(design, population, supporting numbers)
Summary · context
Based on a systematic literature review (SLR) and Bayesian network meta-analysis (NMA), the efficacy and safety of semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide 5, 10 and 15 mg were compared in adults without type 2 diabetes, and with either obesity (body mass index [BMI] ≥ 30 kg/m2</sup…
Summary · context
Following a stringent heterogeneity assessment, six of 42 randomised controlled trials identified in the SLR were included in the NMA.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4182077817
24HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome
In the network meta-analysis, all interventions had a comparable safety profile.
In plain wordsIn adults with obesity or overweight without type 2 diabetes, pooled tirzepatide, liraglutide and semaglutide interventions had a comparable overall safety profile.
Peptide
Tirzepatide
Outcome
Not applicableOverall safety profile
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
All interventions had a comparable safety profile.
2 context sentences(design, population, supporting numbers)
Summary · context
Based on a systematic literature review (SLR) and Bayesian network meta-analysis (NMA), the efficacy and safety of semaglutide 2.4 mg, liraglutide 3 mg and tirzepatide 5, 10 and 15 mg were compared in adults without type 2 diabetes, and with either obesity (body mass index [BMI] ≥ 30 kg/m2</sup…
Summary · context
Following a stringent heterogeneity assessment, six of 42 randomised controlled trials identified in the SLR were included in the NMA.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4182077818

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
12 Oct 2026, 11:11 UTC
Study results updated
Versions 2 to 3
9 Oct 2026, 03:07 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials.

Summary

Results from this study24

Studies that did not test the peptide alone3

Version history

Subjects

Publication types

MeSH terms

Keywords